Patient Global Impression of Change (PGIC)
Also known as: PGIC, Patient Global Impression of Change Scale
The Patient Global Impression of Change is a single-item, seven-point rating scale asking patients to report their overall impression of change since treatment initiation. Originally published by William Guy in the ECDEU Assessment Manual in 1976, the PGIC has become a standard co-primary endpoint in clinical trials assessing treatment efficacy. The scale is endorsed by the FDA as a patient-reported outcome measure for demonstrating clinical benefit. Despite its simplicity, the PGIC captures patients' holistic perception of improvement—integrating symptom reduction, functional recovery, and subjective well-being.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Recommended for: primary or co-primary outcome in clinical trials assessing treatment benefit from patient perspective; endpoint assessment in chronic disease management; complementing objective measures (symptom scales, functional assessments) to capture holistic benefit; treatment satisfaction and acceptability evaluation; generating evidence for FDA labeling claims; qualitative research exploring patient experience of treatment.
Strengths & limitations
- Patient-centered outcome—directly measures what matters most to patients: overall sense of improvement or worsening
- FDA-endorsed—recognized by regulatory agencies as a valid patient-reported outcome measure for evidence generation
- Exceptional simplicity—single item, <1 minute, eliminates response burden and floor/ceiling effects of multi-item scales
- Clinically meaningful—integrates symptom improvement, functional recovery, side effect tolerability, and subjective well-being into one holistic rating
- Responsive to treatment—sensitive to meaningful clinical change even when specific symptom scales show modest shifts
- Complements objective measures—captures patient experience not fully reflected in clinician ratings or biomarkers; rich data for treatment decision-making
- Global impression may obscure specific domains—patient perception of 'much improved' could reflect symptom improvement, improved coping without symptom change, or reduced side effects; cannot distinguish mechanisms
- Vulnerable to response bias—influenced by patient expectations, placebo effect, social desirability (positive reporting), or depression (negative reporting)
- Lacks comparison baseline—respondent must retrospectively compare current state to baseline; memory and mood influence recall
- Limited on its own for diagnosis or severity grading—a PGIC of 5 doesn't specify whether patient improved from severe to moderate or minimal to none; absolute severity unknown
- Susceptible to ceiling/floor effects—respondents often cluster at 6–7 (much improved) in successful trials, limiting discrimination between strong responders
- No subscales or item content detail—single rating provides no information about which symptoms improved or which domains remain impaired
Frequently asked
Is PGIC really just a placebo measure?
No. While PGIC is influenced by expectation and placebo response, it captures genuine patient-centered benefit. A patient reporting PGIC 6 likely experienced meaningful symptom improvement, functional recovery, or enhanced coping. PGIC complements (not replaces) objective measures; together, they define true treatment success.
How do I interpret PGIC if the patient has worsened objectively but reports PGIC 4 (no change)?
Discordance between objective worsening and reported no-change may reflect: (1) patient adjustment or acceptance despite symptom increase, (2) improved functioning in unmeasured domains (relationships, purpose), or (3) expectation-setting (patient expected worse, so no change seems positive). Interview to clarify: 'You report no change, yet your symptoms have worsened. Tell me about that.' Objective decline warrants intervention despite reported stability.
Should I use PGIC as my primary outcome or secondary?
In regulatory trials, PGIC is often a co-primary outcome alongside objective measures. In clinical practice, PGIC informs treatment decisions but should be integrated with symptom severity, functional capacity, and safety. A single PGIC score should not drive treatment discontinuation; consistency across measures is the ideal.
How do I reduce response bias in PGIC?
Administer PGIC without leading language (neutral tone), at pre-specified timepoints (avoid asking unexpectedly when clinician hopes for positive results), and with reminder that honest feedback—positive or negative—helps treatment planning. Combine with objective measures to reduce inflation of perceived benefit.
Sources
- Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, US Department of Health, Education, and Welfare. link ↗
- Farnik, M., & Pierzchala, W. (2012). Instruments to assess fatigue in neurology. Neurological Sciences, 33(5), 1015–1020. link ↗
- FDA. (2009). Guidance for Industry on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Center for Drug Evaluation and Research (CDER). link ↗
How to cite this page
ScholarGate. (2026, June 3). Patient Global Impression of Change (PGIC). ScholarGate. https://scholargate.app/en/clinical-psychology/patient-global-impression-change
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Clinical Global Impressions ScaleClinical Psychology↔ compare
- Patient Health Questionnaire-9Clinical Psychology↔ compare
- Quick Inventory of Depressive SymptomatologyClinical Psychology↔ compare
- Sheehan Disability ScaleClinical Psychology↔ compare